Essential Evidence Plus

What Essential Evidence Plus does

Essential Evidence Plus (EE+) is a subscription-based clinical decision support platform that aggregates evidence-based medicine resources for practicing clinicians at the point of care. Operated as a subsidiary of John Wiley & Sons, Inc. (NYSE: JW.A) and headquartered in Hoboken, New Jersey, EE+ combines a curated content library — over 810 disease and symptom topics, 8,047 POEMs (Patient Oriented Evidence that Matters) research summaries accumulated since 1994, 9,440 Cochrane Systematic Reviews, and 571 interactive decision support and risk tools — with diagnostic calculators (2,500+ covering signs, symptoms, lab tests, and imaging) and a dermatology image viewer. Content is produced and continuously updated under Editor-in-Chief Dr. Mark H. Ebell and 16+ associate editors from leading academic institutions through quarterly automated evidence identification and annual/biennial topic refreshes.

The platform is delivered as a web application with Progressive Web App (PWA) support, enabling installation on iOS and Android home screens for bedside use, and integrates with PubMed via an enhanced search layer offering practice guideline, systematic review, and diagnosis/treatment/prognosis filters. Authentication supports Google and Facebook social sign-in alongside standard credentials, and the platform is committed to WCAG 2.1 A/AA and Section 508 accessibility compliance.

EE+ pursues a hybrid go-to-market combining self-serve individual annual subscriptions with a 30-day freemium trial and direct enterprise sales into hospitals, academic medical centers, and healthcare organizations. Revenue is supplemented by live CME courses delivered by editorial staff around the country and a weekly podcast (Primary Care Update) offering CME credit. All primary customer segments — primary care clinicians, hospitalists, emergency physicians, and medical trainees — are addressed through a horizontal segmentation approach, and pricing is not publicly disclosed for any tier.

Name

Essential Evidence Plus

Legal name

John Wiley & Sons, Inc.

Website

https://essentialevidenceplus.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Short description

Essential Evidence Plus is a Wiley-owned clinical decision support platform serving primary care, hospitalist, and emergency physicians with curated evidence-based medicine content, including 8,000+ POEMs, 9,400+ Cochrane reviews, 800+ disease topics, and interactive diagnostic calculators delivered via web and mobile.

Ownership category

akta.pro rank

Product category

Clinical Decision Support Software

NAICS

Other Scientific and Technical Consulting Services (54169)

SIC

Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Evidence-Based Guidelines, Knowledge Management & Content Authoring (HLACAGAD)

akta.pro secondary industries

Medical & Clinical Reference (Physicians, Nursing, Allied Health) (EDAGAGAA), Healthcare & Clinical Professional Development (CME/CE) (EDAGANAJ)

Keywords

• Evidence-based medicine
• Clinical decision support
• Point-of-care reference
• Medical literature summaries
• Cochrane systematic reviews

Headquarters

HQ city

Hoboken

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Individual Subscriptions: Annual membership subscriptions for individual healthcare professionals, offering access to all content including Essential Evidence Topics, POEMs, Cochrane reviews, decision support tools, and diagnostic calculators. 30-day free trial available.
2. Institutional Access: Organizational/institutional subscriptions for hospitals, academic medical centers, and healthcare systems providing multi-user access to the platform.
3. CME Courses: Live continuing medical education courses delivered by EE+ editors around the country, featuring interactive discussions based on latest POEMs, guidelines, and Cochrane reviews. Contact-based sales for course scheduling.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Essential Evidence Plus is a subscription-based clinical decision support platform that delivers evidence-based medicine reference content and interactive tools to practicing clinicians at the point of care. Its offering bundles over 800 disease and symptom topics, more than 8,000 POEMs research summaries, over 9,400 Cochrane Systematic Reviews, and 570+ interactive decision support and diagnostic calculators, with content updated through a monthly review of 100+ journals. Customers access the platform via web and mobile PWA, with separate individual clinician subscriptions and institutional licenses for hospitals, academic medical centers, and healthcare systems, supplemented by live CME courses delivered by the editorial team.

Product overview

Essential Evidence Plus is a comprehensive, evidence-based clinical decision support platform designed primarily for primary care clinicians, hospitalists, and emergency physicians. The core platform centers on Essential Evidence Topics (800+ disease/symptom overviews with evidence-graded recommendations) integrated with multiple content modules including POEMs Research Summaries (8,000+ clinical study summaries), Cochrane Systematic Reviews (9,400+ gold-standard systematic reviews), Decision Support Tools (570+ interactive clinical algorithms and risk scores), Diagnostic Test Calculators (2,500+ calculators for signs/symptoms and test accuracy), History and Physical Exam Calculators (270+ examination-based tools), and the Derm Expert Image Viewer (1,000 dermatological images). The platform is supplemented by daily/weekly/monthly POEM email alerts, the Primary Care Update podcast, live CME courses, and an enhanced PubMed search. Content is delivered via web app with mobile PWA support and updated continuously through a quarterly automated process with annual/biennial extensive updates.

Differentiator

Problem solved

Functional benefit

Products and services

• Essential Evidence Plus Subscription Platform Subscription-based web and mobile PWA clinical decision support platform bundling 800+ Essential Evidence Topics, 8,000+ POEMs, 9,400+ Cochrane Systematic Reviews, and 2,500+ interactive decision support and diagnostic calculators; sold as individual annual memberships or institutional licenses to hospitals, academic medical centers, and healthcare systems, with a 30-day free trial for individual users.
• Live CME Courses Highly interactive, evidence-based continuing medical education sessions delivered in-person around the country by EE+ editors; each session is 30 minutes covering 12-15 new studies, guidelines, or Cochrane reviews and arranged through dedicated sales and editorial contact.

Quantifiable outcome

• Content reviewed from over 100 journals monthly for POEMs
• +2 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature8 records

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Isabel Healthcare: Differential diagnosis decision support tool used by clinicians to broaden diagnostic considerations. It overlaps with EE+'s decision support calculators and diagnostic test calculators but specializes in DDx generation.
• OpenEvidence: AI-native clinical Q&A platform providing citation-backed answers to clinician questions. It threatens traditional CDS browsing workflows by offering a conversational alternative to EE+'s topic-and-calculator browsing experience.
• VisualDx: Visual diagnostic decision support system focused on dermatology and image-based differential diagnosis, comparable to EE+'s Derm Expert module. It overlaps with the dermatology image viewer component of EE+ but goes deeper on AI-augmented image recognition.

Broad incumbents

• Micromedex: IBM's evidence-based drug and clinical reference solution used at the point of care by hospitals and clinicians. It shares EE+'s institutional point-of-care reference positioning but is much broader in scope.
• Lexicomp: Wolters Kluwer's drug information and clinical reference solution widely used by hospitals and clinicians. While drug-information focused, it shares EE+'s point-of-care reference use case and competes for the same institutional budget.
• ClinicalKey: Elsevier's broad clinical reference and decision support platform combining books, journals, guidelines, and CDS tools. It overlaps with EE+ on the evidence-based CDS layer but as part of a much wider content portfolio aimed at institutions.

Direct peers

• UpToDate: Wolters Kluwer's flagship evidence-based clinical decision support platform used by clinicians at the point of care. It is the category leader and directly competes with EE+ in providing graded, topic-based clinical guidance and decision support for primary care and hospital medicine.
• BMJ Best Practice: BMJ's evidence-based clinical decision support platform providing topic summaries, treatment guidance, and calculators used by clinicians globally. It overlaps directly with EE+ in primary care CDS use cases and competes on editorial credibility and global reach.
• DynaMed: EBSCO's evidence-based point-of-care CDS tool offering graded recommendations, topic summaries, and decision-support calculators for clinicians. It competes head-to-head with EE+ across primary care, hospitalist, and emergency medicine workflows.
• Epocrates: Point-of-care clinical reference app widely used by primary care clinicians for drug information, disease reference, and clinical decision support. It competes with EE+ for the same clinician persona and subscription-driven mobile use case.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Essential Evidence Plus